Psychopharmacology research for individuals with mental retardation: Methodological issues and suggestions

Research in Developmental Disabilities

Volumn 24, Issue 3, 2003, Pages 149-157

  Matson, Johnny L ^a   Bielecki, JoAnne ^a   Mayville, Stephen B ^a   Matson, Michael L ^b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b NONE

Author keywords

Behavioral assessment; Mental retardation; Psychopharmacology research

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

AKATHISIA; ARTICLE; ATHETOSIS; BEHAVIOR THERAPY; CAREGIVER; CHOREA; CLINICAL TRIAL; DRUG QUALITY; DRUG RESEARCH; DYSTONIA; ENVIRONMENTAL FACTOR; EXTRAPYRAMIDAL SYMPTOM; FAMILY; FOLLOW UP; HUMAN; MEDICAL LITERATURE; MENTAL DEFICIENCY; METHODOLOGY; MUSCLE RIGIDITY; NEUROTOXICITY; OROFACIAL DYSKINESIA; PARKINSONISM; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; QUALITY CONTROL; TARDIVE DYSKINESIA; TIC; TREATMENT OUTCOME; TREMOR;

EID: 0038329330     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-4222(03)00030-1     Document Type: Article

References (28)

1. Aman M.G. Considerations in the use of psychotropic drugs in elderly mentally retarded persons. Journal of Mental Deficiency Research. 34:1990;1-10.
2. Aman M.G., De-Smedt G., Derivan A., Lyons B., Findling R.L. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. American Journal of Psychiatry. 159:2002;1337-1346.
3. Aman M.G., Singh N.N. A critical appraisal of recent drug research in mental retardation: The Coldwater studies. Journal of Mental Deficiency Research. 30:1986;203-216.
4. Aman, M. G., & Singh, N. N. (1988). Psychopharmacology of the developmental disabilities. Berlin: Springer-Verlag.
5. Aman M.G., Singh N.N., White A.J. Caregiver perceptions of psychotropic medication in residential facilities. Research in Developmental Disabilities. 8:1987;449-465.
6. Baldessarini, R. J., & Tarsey, D. (1978). Tardive Dyskinesia. In M. A. Lipton, A. DiMascio, & K. F. Killam (Eds.), Psychopharmacology: A generation of progress. New York: Raven Press.
7. Baumeister A.A., Sevin J.A. Pharmacologic control of aberrant behavior in the mentally retarded: Toward a more rational approach. Neuroscience and Biobehavioral Reviews. 14:1990;253-262.
8. Breuning, S. E., & Poling, A. D. (1982). Pharmacotherapy. In J. L. Matson & R. P. Barrett (Eds.), Psychopathology in the mentally retarded (pp. 195-251). Philadelphia, PA: Grune & Stratton, Inc.
9. Burgio L.D., Page T.J., Capriotti R.M. Clinical behavioral pharmacology: Methods for evaluating medications and contingency management. Journal of Applied Behavior Analysis. 18:1985;45-59.
10. Campbell, D. T., & Stanley, J. C. (1963). Experimental and quasi-experimental designs for research. Boston: Houghton Mifflin Company.
11. Carr E.G. The motivation of self-injurious behavior: A review of some hypotheses. Psychological Bulletin. 84:1977;800-816.
12. Gardos G., Casey D.E., Cole J.O., Perenyi A., Kocsis E., Mihalya A., Samson J.A., Conley C. Ten year outcome of Tardive Dyskinesia. American Journal of Psychiatry. 151:1994;836-841.
13. Gardos G., Cole J.O., LaBrie R. The assessment of Tardive Dyskinesia. Archives of General Psychiatry. 34:1977;1206-1212.
14. Gerlach J., Casey D.E. Tardive Dyskinesia. Acta Psychiatrica Scandinavica. 77:1988;369-378.
15. Harris, S. L., Allessandri, M., & Gill, M. J. (1991). Training parents of developmentally disabled children. In J. L. Matson & J. A. Mulick (Eds.), Handbook of mental retardation (2nd ed., pp. 373-381). New York: Pergamon Press.
16. Haynes, S. N., & O'Brien, W. H. (2000). Principles and practice of behavioral assessment. New York: Plenum Press.
17. Iwata B.A., Dorsey M.F., Slifer K.J., Bauman K.E., Richman G.S. Toward a functional analysis of self-injury. Analysis and Intervention in Developmental Disabilities. 2:1982;3-20.
18. Kalachnik J.E., Hanzel T.E., Harder S.R., Bauernfeind J.D. Antiepileptic drug behavioral side effects in individuals with mental retardation and the use of behavioral measurement techniques. Mental Retardation. 33:1995;374-382.
19. Llorca P.M., Chereau I., Bayle F.J., Lancon C. Tardive Dyskinesias and antipsychotics: A review. European Psychiatry. 17:2002;129-138.
20. Locascio J.J., Malone R.P., Small A.M., Kafantaris V., Ernst M., Lynch N.S., Overall J.E., Campbell M. Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacology Bulletin. 27:1991;119-126.
21. Martin J.E., Agran M. Psychotropic and anticonvulsant drug use by mentally retarded adults across community residential and vocational placements. Applied Research in Mental Retardation. 6:1985;33-49.
22. Matson J.L., Bamburg J.W., Mayville E.A., Pinkston J., Bielecki J., Kuhn D., Smalls Y., Logan J.R. Psychopharmacology and mental retardation: A 10-year review (1990-1999). Research in Developmental Disabilities. 21:2000;263-296.
23. Rush A.J., Frances A. Treatment of psychiatric and behavioral problems in mental retardation. American Journal on Mental Retardation. 105:2000;159-227.
24. Simpson G.M., Pi E.H., Sramek J.J. An update on Tardive Dyskinesia. Hospital and Community Psychiatry. 37:1986;362-369.
25. Singh N.N., Millichamp Pharmacological treatment of self-injurios behavior in persons with mental retardation. Journal of Autism and Developmental Disabilities. 15:1986;257-267.
26. Sprague J.R., Horner R.H. Functional assessment and intervention in community settings. Mental Retardation and Developmental Disabilities Research Reviews. 1:1995;89-93.
27. Sultzer-Azaroff, B., & Meyer, R. G. (1991). Behavior analysis for lasting change. New York: Holt, Rinehart, and Winston.
28. Wolfensberger W. Social role valorization: A proposed new term for the principle of normalization. Mental Retardation. 21:1983;234-239.